Immunomodulators in Lymphoma
- 19 March 2020
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 21 (4) , 1-13
Abstract
Opinion statement Lymphomas are highly heterogeneous tumors and different histologies are characterized by significant differences in biology. Despite the structural and molecular differences between lymphoma types, it is well recognized that the tumor microenvironment plays a critical role in the lymphoma survival and growth. Over the past few years, understanding of this notion has brought immunotherapy to the forefront of lymphoma treatment by targeting the tumor microenvironment in order to produce an effective anti-tumor response. Thus, the area of lymphoma therapy has changed dramatically within the past few years with the use of checkpoint inhibitors and more recently CAR T-cells. Remarkable results have been reported in some lymphoma types but responses vary significantly between different histologies. Future approaches will focus on combination strategies that will attack lymphoma cells in addition to activating immune responses. These strategies include combinations of different checkpoint blocking antibodies, combinations of checkpoint blocking antibodies with agonistic antibodies, immunomodulatory agents, small molecule inhibitors or CAR T-cells, and armored CAR T-cells. A number of clinical trials testing such combinations are currently under way. In this review, we discuss strategies to modulate the immune response in lymphoma. We specifically address the obstacles to effective activation of the immune system against malignant B-cells and review the current approaches that try to overcome these barriers.Keywords
This publication has 87 references indexed in Scilit:
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJournal of Clinical Investigation, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell LymphomaCancer Cell, 2011
- Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cellsLeukemia, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences, 2010
- Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin LymphomaClinical Cancer Research, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's LymphomaCancer Research, 2006